3'-Azido-2',3'-dideoxythymidine-5'-triphosphate, Sodium salt
For research use only!
Shipping: shipped on blue ice
Storage Conditions: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.
Shelf Life: 12 months after date of delivery
Molecular Formula: C10H16N5O13P3 (free acid)
Molecular Weight: 507.18 g/mol (free acid)
Purity: ≥ 95 % (HPLC)
Form: clear aqueous solution
Concentration: 100 mM - 110 mM
pH: 7.5 ±0.5
Spectroscopic Properties: λmax 267 nm, ε 10.9 L mmol-1 cm-1 (Tris-HCl pH 7.5)
Suppression of HIV-type 1 replication
Removal of iron from transferrin
Inhibition of telomerase activity
Inhibition of thymidine phosphorylation
High binding affinity to HIV-1 mutants
 Sayed et al. (2009) AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J. Neurobiology 15 (4):343.
 D´Andrea et al. (2008) AZT: an old drug with new perspectives. Curr. Clin. Pharmacol. 3 (1):20.
 Liu et al. (2007) 3'-Azido-2´,3'-dideoxynucleoside 5'-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells. Nucleic Acid Res. 35 (21):7140.
 Lynx et al. (2006) 3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: A possible mechanism of AZT hepatotoxicity. Biochem. Pharmacol. 71 (9):1342.
 Jamburuthugoda et al. (2005) Kinetic evidence for interaction of HIV type 1 reverse transcriptase with the 3'-OH of the incoming dTTP substrate. Biochemistry 44 (31):10635.
Coulier et al. (2008) Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry. Proteomics Clin. Appl. 2:1557.
Cruchaga et al. (2005) Inhibition of Phosphorolysis Catalyzed by HIV-1 Reverse Transcriptase Is Responsible for the Synergy Found in Combinations of 3'-Azido-3'-deoxythymidine with Nonnucleoside Inhibitors Biochemistry 44 (9):3535.
Akeb et al. (2001) The production and evaluation of antibodies for enzyme immunoassay of AZTTP. Nucleosides Nucleotides Nucleic Acids. 20:243.
Fletcher et al. (2000) Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIVinfected persons. AIDS 14:2137.
Faraj et al. (2000) Effects of beta-L-3'-azido-3'-deoxythymidine 5'-triphosphate on host and viral DNA polymerases. Antiviral Res. 47:97.
Font et al. (1999) Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry. Antimicrob. Agents Chemother. 43:2964.
Elimadi et al. (1997) Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation. Br. J. Pharmacol. 121:1295.
Jaju et al. (1995) Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer. J. Biol. Chem. 270:9740.
Tornevik et al. (1995) Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829.